WO1995027697A1 - Derive de la 22-thiavitamine d¿3? - Google Patents
Derive de la 22-thiavitamine d¿3? Download PDFInfo
- Publication number
- WO1995027697A1 WO1995027697A1 PCT/JP1995/000699 JP9500699W WO9527697A1 WO 1995027697 A1 WO1995027697 A1 WO 1995027697A1 JP 9500699 W JP9500699 W JP 9500699W WO 9527697 A1 WO9527697 A1 WO 9527697A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- compound according
- hydrogen atom
- general formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 260
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 58
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 23
- 238000006243 chemical reaction Methods 0.000 claims description 98
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- 125000006239 protecting group Chemical group 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- 229910014033 C-OH Inorganic materials 0.000 claims description 2
- 229910014570 C—OH Inorganic materials 0.000 claims description 2
- 238000006317 isomerization reaction Methods 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 210000002510 keratinocyte Anatomy 0.000 abstract description 10
- 150000003710 vitamin D derivatives Chemical group 0.000 abstract description 6
- 125000004434 sulfur atom Chemical group 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 229910052717 sulfur Inorganic materials 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003966 growth inhibitor Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 261
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 189
- -1 3- (n-propyl) hexyl group Chemical group 0.000 description 160
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 136
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 136
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 105
- 238000012746 preparative thin layer chromatography Methods 0.000 description 81
- 239000012230 colorless oil Substances 0.000 description 66
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 63
- 239000000203 mixture Substances 0.000 description 51
- 239000000243 solution Substances 0.000 description 44
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 28
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 28
- 239000002904 solvent Substances 0.000 description 27
- 239000012280 lithium aluminium hydride Substances 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000000746 purification Methods 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- 229910021538 borax Inorganic materials 0.000 description 13
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 13
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 13
- 239000004328 sodium tetraborate Substances 0.000 description 13
- 235000010339 sodium tetraborate Nutrition 0.000 description 13
- 239000012300 argon atmosphere Substances 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- 235000010724 Wisteria floribunda Nutrition 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 229910015900 BF3 Inorganic materials 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 101001128742 Homo sapiens Nucleoside diphosphate kinase homolog 5 Proteins 0.000 description 6
- 102100032210 Nucleoside diphosphate kinase homolog 5 Human genes 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 6
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 5
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 150000005671 trienes Chemical group 0.000 description 4
- 229960001124 trientine Drugs 0.000 description 4
- CUGJLGLVJWHPDU-UHFFFAOYSA-N 2-methyl-4-sulfanylbutan-2-ol Chemical compound CC(C)(O)CCS CUGJLGLVJWHPDU-UHFFFAOYSA-N 0.000 description 3
- WRFWAYDBNCOWRA-UHFFFAOYSA-N 3,4-dichloro-1-(6-iodo-4-oxo-2-thiophen-2-ylquinazolin-3-yl)pyrrole-2,5-dione Chemical compound O=C1C(Cl)=C(Cl)C(=O)N1N1C(=O)C2=CC(I)=CC=C2N=C1C1=CC=CS1 WRFWAYDBNCOWRA-UHFFFAOYSA-N 0.000 description 3
- 101150101112 7 gene Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 125000004448 alkyl carbonyl group Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 150000003704 vitamin D3 derivatives Chemical class 0.000 description 3
- PMBXCGGQNSVESQ-UHFFFAOYSA-N 1-Hexanethiol Chemical compound CCCCCCS PMBXCGGQNSVESQ-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical group N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 2
- 239000004210 ether based solvent Substances 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LHOIAFAJRRSRRQ-UHFFFAOYSA-N 1,1-dimethyl-2-pyridin-4-ylhydrazine Chemical compound CN(C)NC1=CC=NC=C1 LHOIAFAJRRSRRQ-UHFFFAOYSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- LAFMRXMLDULLEX-UHFFFAOYSA-N 2-methyl-5-sulfanylpentan-2-ol Chemical compound CC(C)(O)CCCS LAFMRXMLDULLEX-UHFFFAOYSA-N 0.000 description 1
- RKJSWWJNIPMEHM-UHFFFAOYSA-N 2-methyl-6-sulfanylhexan-2-ol Chemical compound CC(C)(O)CCCCS RKJSWWJNIPMEHM-UHFFFAOYSA-N 0.000 description 1
- KRIMXCDMVRMCTC-UHFFFAOYSA-N 2-methylhexan-2-ol Chemical compound CCCCC(C)(C)O KRIMXCDMVRMCTC-UHFFFAOYSA-N 0.000 description 1
- 125000004715 3-methylbutylthio group Chemical group CC(CCS*)C 0.000 description 1
- NIFWBIZUAZVUMO-UHFFFAOYSA-N 3-phenyloxaziridine Chemical compound N1OC1C1=CC=CC=C1 NIFWBIZUAZVUMO-UHFFFAOYSA-N 0.000 description 1
- GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- AQVKVBCOUZDFRE-UHFFFAOYSA-N CS(=O)C.[Ca] Chemical compound CS(=O)C.[Ca] AQVKVBCOUZDFRE-UHFFFAOYSA-N 0.000 description 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HRKQOINLCJTGBK-UHFFFAOYSA-N dihydroxidosulfur Chemical compound OSO HRKQOINLCJTGBK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- FQTIYMRSUOADDK-UHFFFAOYSA-N ethyl 3-bromopropanoate Chemical compound CCOC(=O)CCBr FQTIYMRSUOADDK-UHFFFAOYSA-N 0.000 description 1
- DXBULVYHTICWKT-UHFFFAOYSA-N ethyl 6-bromohexanoate Chemical compound CCOC(=O)CCCCCBr DXBULVYHTICWKT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- JHYNXXDQQHTCHJ-UHFFFAOYSA-M ethyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC)C1=CC=CC=C1 JHYNXXDQQHTCHJ-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960004251 hydroquinine Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
- LTFUIUOXHVKIAE-UHFFFAOYSA-M lithium;ethanethioate Chemical compound [Li+].CC([O-])=S LTFUIUOXHVKIAE-UHFFFAOYSA-M 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OTOYXUPFIMDEIA-UHFFFAOYSA-N o-ethyl 5-oxohexanethioate Chemical compound CCOC(=S)CCCC(C)=O OTOYXUPFIMDEIA-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- MVJKXJPDBTXECY-UHFFFAOYSA-N trifluoroborane;hydrate Chemical compound O.FB(F)F MVJKXJPDBTXECY-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Definitions
- the present invention relates to novel vitamin D 3 derivatives. More particularly position 22 on Vitamin D 3 derivatives and a manufacturing method thereof which is substituted with a sulfur atom.
- the present invention also relates to intermediates useful for producing the compounds and methods for producing the same. Background art
- active vitamin D 3 has many physiological activities such as a calcium metabolism regulating effect, a differentiation inducing effect, an immunomodulating effect, and the like.
- Vitamin D e.g., 1, 25-dihydroxyvitamin D 3
- Vitamin D e.g., 1, 25-dihydroxyvitamin D 3
- 1 alpha, 25-dihydroxy vitamin D 3 may, by the administration of long-term and continuous ⁇ has the drawback of causing hypercalcemia, such as anti-tumor agents, for use as such as an anti-rheumatic agent Is not suitable.
- many vitamin D derivatives have recently been synthesized for the purpose of separating the action of these vitamin Ds, and their biological activities are being studied.
- the present inventors have studied the vitamin D derivative and found that vitamin D in which the 22nd position is substituted with a sulfur atom has a strong keratinocyte growth inhibitory action.
- the present invention relates to a 22-thiavitamin D derivative represented by the following general formula (I) and a method for producing the same.
- R 2 represents a hydrogen atom or a hydroxyl group
- R 3 represents a hydrogen atom or a hydroxyl group.
- the present invention also relates to a synthetic intermediate useful for producing the compound represented by the general formula (I) and a method for producing the intermediate.
- Figure 1 is a graph showing the 1, 2 5-growth inhibitory effect of Hitokerachi Nosai Bok at each concentration dihydroxyvitamin D 3.
- FIG. 2 is a graph showing the effect of inhibiting the growth of human keratinocytes at various concentrations of the compound of Example 88.
- 1 alpha is a graph showing the growth inhibitory effect of Hitokerachi Nosai Bok at each concentration of 2 5 dihydroxyvitamin D 3.
- FIG. 4 is a graph showing the effect of inhibiting the growth of human keratinocytes at various concentrations of the compound of Example 33.
- FIG. 5 is a graph showing the effect of inhibiting the growth of human keratinocytes at various concentrations of the compound of Example 35.
- the present invention provides a 22-thiavitamin D derivative represented by the following general formula (I).
- Ri represents an alkyl group having 1 to 10 carbon atoms which may be substituted with one or more hydroxyl groups
- R 2 represents a hydrogen atom or a hydroxyl group
- R 3 represents a hydrogen atom or a hydroxyl group.
- R 3 is preferably a hydroxyl group.
- R ⁇ is preferably an alkyl group having 1 to 10 carbon atoms and substituted by one or more hydroxyl groups, and particularly preferably represented by the following general formula (III)
- R 4 and R 5 are the same or different and each represent a hydrogen atom or a hydroxyl group, but are not a hydroxyl group at the same time.
- M is an integer from 1 to 4
- n is an integer from 0 to 2. Is preferable.
- R 4 and R 5 are particularly preferably hydrogen atoms.
- R 2 represents a hydrogen atom or a hydroxyl group
- the coordination represented by is particularly preferred.
- the present invention relates to a process for producing a 2 2-position of vitamin D 3 derivatives substituted by sulfur atoms. That is, the present invention provides a compound represented by the general formula (XV):
- R 25 represents an alkyl group having 1 to 10 carbon atoms which may be substituted with one or more hydroxyl groups
- R 26 and R 27 are the same or different and represent a hydrogen atom or a protecting group.
- R 28 represents a hydrogen atom or a hydroxyl group
- R 25 represents an alkyl group having 1 to 10 carbon atoms which may be substituted with one or more hydroxyl groups
- R 2 e and R 27 are the same or different and each represent a hydrogen atom or a protecting group.
- R 28 represents a hydrogen atom or a hydroxyl group
- the present invention provides a synthetic intermediate useful for producing the compound represented by the general formula (I) and a method for producing the same.
- R 6 and R 7 are the same or different and each represent a hydrogen atom or a protecting group, and R 8 represents an optionally substituted alkyl group having 1 to 10 carbon atoms).
- R 15 and R ie are the same or different and each represents a hydrogen atom or a protecting group, (viii) 1 hard Rei_110 ⁇ 1 Matawa 00)
- R 19 and R 2D are the same or different and each represent a hydrogen atom or a protecting group
- R 21 represents an alkyl group having 1 to 10 carbon atoms which may have a substituent
- a 3 represents — Indicates CHOH—or one CO—
- R 17 and R 18 are the same or different and each represent a hydrogen atom or a protecting group.
- a 2 represents one CHOH— or one CO—
- R 22 and R 23 are the same or different and each represent a hydrogen atom or a protecting group
- R 24 represents an alkyl group having 1 to 10 carbon atoms which may have a substituent
- a 4 represents — Indicates CHOH—or one CO—
- examples of R 8 , Ru, R 14 , R 21 , and R 24 are preferably an alkyl group having 1 to 10 carbon atoms and substituted by one or more hydroxyl groups, and a general formula an)
- R 4 and R 5 are the same or different and each represent a hydrogen atom or a hydroxyl group, but are not a hydroxyl group at the same time.
- M is an integer from 1 to 4
- n is an integer from 0 to 2. Indicates
- Particularly preferred is a group represented by the general formula (III), wherein R 4 and R 5 are hydrogen atoms.
- the alkyl group in the alkyl group having 1 to 10 carbon atoms which may be substituted with a hydroxyl group indicates a linear or branched alkyl group, such as a methyl group, an ethyl group, an n-propyl group, Examples include i-propyl group, n-butyl group, i-butyl group, s-butyl group, t-butyl group, pentyl group, hexyl group, heptyl group, octyl group, nonyl group, decanyl group and the like.
- Examples of the number of substituted hydroxyl groups in an alkyl group having 1 to 10 carbon atoms which may be substituted with one or more hydroxyl groups include, for example, 0, 1, 2, 3 and the like. And preferably 1 or 2, and more preferably 1.
- alkyl group having 1 to 10 carbon atoms substituted with one or more hydroxyl groups examples include 3-hydroxy-3-methylbutyl group, 2-hydroxy-3-methylbutyl group and 4-hydroxy-13-methylbutyl group. , 2,3-dihydroxy-1-methylbutyl group, 2,4-dihydroxy-3-methylbutyl group, 3,4-dihydroxy-3-methylbutyl group, 3-hydroxy_3-ethylpentyl group, 2-hydroxyl group 1, 3-ethylpentyl, 4-hydroxy-3-ethylpentyl, 2,3-dihydroxy-13-ethylpentyl, 2,4-dihydroxyl-3-ethylpentyl, 3,4-dihydroxypentyl-3-ethylpentyl, 4-Hydroxy 4-methylpentyl, 3-hydroxy 4-methylpentyl, 5-hydroxy 41-methylpentyl, 3,4-dihydroxy ⁇ 4-methylpentyl group, 3,5-dihydroxy 4-methylpenty
- 6-dihydroxy-5-methylhexyl group 5,6-dihydroxy-1-5-methylhexyl group, 5-hydroxy-6-methylheptyl group, 6-hydroxy-6-methylheptyl group, 7-hydroxyl group
- 6-methylheptyl group 5, 6-dihydroxy 6-methylheptyl group, 5,7-dihydroxy 6-methylheptyl group, 6,
- the protecting group in the present invention includes an acyl group, a substituted silyl group, a substituted alkyl group and the like, and is preferably an acyl group or a substituted silyl group.
- the acyl group in the present invention may be a formyl group, an i-substituted alkylcarbonyl group optionally having a substituent, an arylcarbonyl group optionally having a substituent, A good aralkylcarbonyl group, a substituted or unsubstituted lower alkylcarbonyl group, a substituted or unsubstituted aryloxycarbonyl group, And preferably a formyl group, a lower alkylcarbonyl group, or a substituted or unsubstituted phenylcarbonyl group, a lower alkyloxycarbonyl group, or a substituent.
- a formyl group an acetyl group, a propionyl group, a butyryl group, a bivaloyl group, or a benzylalkyloxycarbonyl group.
- benzyl ethoxycarbonyl, t-butoxycarbonyl, benzyloxycarbonyl and the like.
- Substituted silyl group means one or more lower alkyl group which may have a substituent, A silyl group substituted with an aryl group which may have a substituent; and preferably a 3-substituted silyl group.
- Preferred examples of the substituted silyl group include a trimethylsilyl group, a triethylsilyl group, a triisopropylsilyl group, a t-butyldiphenylsilyl group, and a t-butyldimethylsilyl group.
- the substituted alkyl group refers to an alkyl group substituted with one or more substituents, and preferred examples of the substituent include an aryl group which may have a substituent and a substituent. And an alkyloxy group which may have a substituent such as an alkyloxy group.
- alkyloxy group which may have a substituent such as an alkyloxy group include, for example, a tetramethylpyroxy-2-yl group in addition to a methoxymethyl group and a 2-methoxyethoxymethyl group.
- Stable group is preferably under acidic conditions as a protecting group of R 6, R 7, R 1 2, R 1 3, is preferably exemplified Ashiru group is al, that Ri Asechiru groups mentioned as particularly preferred o ⁇ 9 ⁇ ⁇ ⁇ R 15 ⁇ 6 ⁇ R l 7 ⁇ ⁇ R l 9 ⁇ R 20 ⁇ R 22 2 3 ⁇ 4 1 3 ⁇ 4 23 Groups, triisopropylsilyl group, t-butyldimethylsilyl group, t-butyldiphenylsilyl group, etc., and particularly preferred is t-butyldimethylsilyl group.
- reducing conditions in the present invention means that a reducing agent is present in the reaction system.
- the reducing agent used herein include borane and trialkylsilane, and preferably include trialkylsilane. And more preferably triethylsilane.
- the basic condition in the present invention indicates that a base is present in the reaction system, and the base used herein may be any as long as it can form thioalcohol.
- Examples include sodium hydroxide and sodium tetraborate, and preferably sodium tetraborate.
- Examples of the substituent in the present invention include a halogen atom, a cyano group, a nitro group, a hydroxyl group, an alkoxy group, an amino group, a mercapto group and an acyloxy group.
- R 8 R n, as listed above, especially preferable examples of the substituents in R 1 4, R 2 1, R 24, hydroxyl, alkoxy, etc. Ashiruokishi group and the like, a hydroxy group as also most preferred .
- the compound of the present invention has a strong keratinocyte proliferation inhibitory action.
- the steric configuration at the 20-position and the steric configuration of the hydroxyl group of the compound of the present invention may be any of R, S or ⁇ ;
- the 1-position is preferably substituted with a hydroxyl group, and the hydroxyl group is more preferably a coordinated one.
- the compounds of the present invention are all novel compounds and are synthesized, for example, as follows.
- reaction path 1 The thiol used as a raw material for synthesis of the side chain beyond the 22nd position was synthesized by the method described in the official gazette of Japanese Patent Application Laid-Open No. 5-55056 / 13 or by the following reaction route 1. Reaction path 1
- Compound (6) as a starting material in Reaction Route 2 is synthesized, for example, by the method of Mu ray am a et al. (Bioorg. Med. Chem. Lett. 2, 1289 (1992)) . After deprotection of the hydroxyl-protecting group of the compound (6), the compound is protected again by an acyl group, preferably an acetyl group, to obtain the compound (8).
- Compound (9) is obtained by subjecting compound (8) to a reductive thioalkylation reaction.
- the reductive thioalkylation is carried out by, for example, a method of reacting boron trifluoride ether complex or boron trifluoride monohydrate and triethylsilane, a method of using a trifluor-acetate monoborane-pyridine complex, or the like. Performed by reacting boron fluoride ether complex and triethylsilane o
- Examples of the solvent used in this reaction include a halogen-based solvent, an ether-based solvent, an aromatic hydrocarbon-based solvent, and the like, preferably a halogen-based solvent, and more preferably dichloromethane.
- the reaction temperature varies depending on the type of the compound used, the reagent, etc., but is generally a temperature at which the 5,7-gen moiety is not isomerized, preferably from 130 ° C to room temperature, and more preferably around 0 ° C. .
- the reaction time varies depending on the amount of reagents and compounds used, etc., but is generally 1 to 12 hours, preferably 3 to 10 hours, and more preferably 5 to 7 hours.
- the compound (9) obtained above is deprotected by a conventional method, and if necessary, the diastereomer is separated. can get. In the case where it is difficult to separate diastereomers in this step, the separation can be achieved by converting the hydroxyl-protecting group at the 1-position and / or the 3-position into an appropriate protecting group, if necessary.
- Compound (13) as a starting material in reaction route 3 is synthesized, for example, by the method of Murayama et al. (Chem. Pharm. Bull. 34, 4410 (1986)).
- an oxygen functional group is introduced into position 16 of compound (13).
- a method for introducing an oxygen functional group for example, a method in which 2- (fuynylsulfonyl) -13-phenyloxaziridine is allowed to act in the presence of a base. And the like, preferably in the presence of a base.
- This reaction is preferably an oxidation reaction using calcium dimethyl sulfoxide which can be performed by a usual oxidation reaction using chromate, dimethyl sulfoxide, or the like.
- This step when the mixture of E and Z of the compound (15) is oxidized with manganese dioxide, only the E-isomer proceeds, and the E-isomer (16) is obtained.
- the unreacted Z-form compound (15) can be stereoselectively led to the Z-form compound (16) as shown in the following reaction route 4 by Wern oxidation or the like. Reaction path 4
- the E-isomer of compound (15) can also be synthesized by the following reaction route 5 ( reaction route 5).
- the starting compound (17) in Reaction Route 5 can be synthesized, for example, according to the method of Muramayama et al. (Chem. Pharm. Bull. 34, 4410 (1986)).
- a protecting group such as 4-fluoro-1,2,4-triazoline-1,3,5-dione, selenium dioxide, chromic acid, and sulfuric acid
- Oxidation with an oxidizing agent such as manganese (m), preferably selenium dioxide, followed by deprotection gives the E-form of compound (15).
- the compound (20) is obtained by adding various thiols to the compound (16) obtained by the above-described method by adding 1,4 as shown in the following reaction route 6.
- Reaction path 6
- R so represents an alkyl group having 1 to 0.10 carbon atoms which may have a substituent.
- This reaction is carried out by a conventional method of 1,4-addition reaction to, ⁇ monounsaturated ketone. Applicable. Examples of this method include a method in which the reaction is carried out under basic conditions, preferably a method using sodium hydroxide and sodium tetraborate, and more preferably a method using sodium tetraborate There is a method.
- the solvent used here varies depending on the reagent used and the like.When sodium tetraborate is used, an ether-based solvent, an alcohol-based solvent, or the like is used alone or as a mixture with water.
- reaction temperature varies depending on the reagents used and the like, but is generally -20 to 60 ° C, preferably 0 to 40 ° C, and more preferably 15 to 25 ° C.
- the reaction time varies depending on the amount of the reagent, compound used and the like, but is generally 3 to 24 hours, preferably 9 to 15 hours, more preferably 12 to 15 hours.
- the compound (20) obtained above can be led to the compound (23) by reduction, deprotection, light irradiation, and thermal isomerization by a conventional method.
- reaction mixture was quenched with a saturated aqueous solution of ammonium chloride, the solution was acidified with 10-hydrochloric acid, extracted with ethyl acetate, and the extract was washed with saturated saline and dried over magnesium sulfate.
- methylmagnesium bromide (0.99M tetrahydrofuran solution, 70 ml, 69.3 mmol) was added to dry tetrahydrofuran (80 ml), cooled to 0 ° C, and added with 5-ethyl bromovalerate (3.66 ml, 23.lmmol) in tetrahydrofuran (10 ml) was added dropwise, stirred at room temperature for 1.5 hours, quenched with a saturated aqueous solution of ammonium chloride, poured into water, extracted with ethyl acetate, and the extract was washed with saturated saline. And dried over magnesium sulfate.
- Example 4 3-Hydroxy-3-n-propyl-11-hexanthiol Ethyl 3-bromopropionate and n-Propyl were prepared in the same manner as in Example 2. The title compound was synthesized from pill magnesium bromide.
- UVA m &] ( nm: 271, 283, 294.
- UVA max nra 270, 281. 292.
- Example 7 1 / 3,5 / 5-diacetoxy-1 20- (3-hydroxy-3-methylbutylthio) pregna-5,7-gen (mixture of R-form and S-form at position 20) Performed in an argon atmosphere A solution of the compound obtained in Example 6 (100 mg, 0.241 mmol) and 3-methyl-3-hydroxy-1-butanethiol (34.7 mg, 0.289 mmol) in dry dichloromethane (0.5 ml) was cooled to 0 ° C. Boron ether complex (35.
- UV max nm 273, 282, 293.
- Example 8 1,3 ⁇ -Diacetoxy 20 (S) — (4-Ethyru 4-Hydroquinequinlthio) Predaner 5,7-Gen and 1/3 / 3-Diacetoxy-20 (R) — (4 1-ethyl-1-4-hydroxyhexylthio) pregner 5,7-gen
- UVA max nm 270, 281, 293.
- UVA max nm 270, 281, 293.
- UV nm 270, 281. 293. 2 OR body:
- UVA max nm 270, 281, 293.
- Example 11 1 ⁇ , 3 / 3-Diacetoxy-1 20 (S) — (5-hydroxy-5-methylhexylthio) predaner 5,7-Gen and 1,3-1, diacetoxy-1 20 (R) — (5 —Hydroxy-1-5-methylhexylthio) pregna-1,5—Gen
- UVA max nm 270, 281, 293.
- Example 12 1,3 3-Diacetoxy 20 (S) — (6-hydroxy-1-6-methylheptylthio) pregna-1,5,7-gen and 1.3 yS—diacetoxy-1 20 (R)-(6 —Hydroxy-1-6-methylheptylthio) predaner 5, 7—gen
- UV m a X nm 270, 281, 293.
- UVA max nm 270, 281, 293.
- Example 14 Hydroxy-3) S— (t-butyldimethylsilyloxy) —20 (S) — (4-Hydroxy-4-methylpentylthio) pregna-5,7—gen and 1, hydroxy-3 — (T-butyldimethylsilyloxy) -120 (R)-(4-hydroxy-4-methylpentylthio) pregner 5,7-gene Under an argon atmosphere, the compound (mixture) (93.3 mg, 0.175 mmol) obtained in Example 9 was dissolved in dry tetrahydrofuran (4 ml), and lithium aluminum hydride (13.3 mg, 0.350 mmol) was added little by little.
- Example 7 Under an argon atmosphere, the compound (mixture) (55. Omg, 0.106 ol) obtained in Example 7 was dissolved in dry tetrahydrofuran (2ral), and lithium aluminum hydride (8.0 mg, 0.212 mmol) was added thereto. After adding little by little, the mixture was stirred at room temperature for 30 minutes. The reaction solution was quenched with a 10% aqueous sodium hydroxide solution, extracted with ethyl acetate, washed with brine, dried over magnesium sulfate, and the solvent was removed under reduced pressure.
- UVA m ax nm 272, 282 , 293.
- Example 16 3-Dihydroxy 20 (S)-(4-ethylethyl 4-hydroquinhexylthio) predaner 5,7-gen
- the 20S form obtained in Example 8 (8.6 mg, 15. dried tetrahydrofuran (1.
- UVAnax nm 271, 282, 294.
- Example 17 1 ⁇ .3 ⁇ -Dihydroxy-20 (R) — (4-ethyl-41-hydroxyhexylthio) pregna-5,7-gen
- UVA raa x nm 27L 282, 294.
- Example 14 Using the 2OR form (23.7 mg, 42.1 / niol) obtained in Example 14, dry tetrahydrofuran (1.5 ⁇ ⁇ 1), tetra- ⁇ -butylammonium fluoride (1 M tetrahydrofuran solution, 1 ml), By a similar operation to that of Example 18, the title compound (10. Omg, 533 ⁇ 4i) was obtained as a colorless oil.
- UVA max nm 271, 282, 294.
- UVA max nm 271, 282, 294.
- UVA.ax nm 271, 282, 294.
- UVA raa x nm 271, 282, 294.
- UVA raax nm 271, 282, 294.
- UV max nm 271, 282, 294.
- UVA.a x nm 271, 282, 294.
- Example 28 1 a 3—Dihydroxy-1- (S) — (3-hydroxy-1-methylbutylthio) -1,9,10-secopregna-1,7,10 (19) —Triene
- UVA roa x nm 263, A mifactnm: 227.
- UVA.ax nm 263, A mi n nm: 227.
- UVA raa x nm 262, mi n nm: 227.
- IB (neat): 3400, 2950, 1460, 1370, 1050cm- 1 .
- UV ma x nra 262 A min nm: 227.
- UVA raax nm 263, ⁇ ,, ⁇ nm: 227.
- UV .ax nm 270, 281, 293.
- Example 43 1 ⁇ , 3 / 3-Bis (t-butyldimethylsilyloxy) 1-16 monohydroxypregna 5,7,17 (E) -triene and 1 y, 3 yS-bis
- UVA.a x nm 270, 281, 293.
- UVA nm 270, 282, 293.
- reaction solution was poured into water, extracted with dichloromethane, washed with saturated saline, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
- UVA max nm 242.258, 270, 281, 293.
- Example 43 A solution of the compound obtained in Example 43 in Z form (347 mg, 0.62 mmol) in dry dichloromethane (2 ml), a solution of trichloromethyl chloroformate (118 zl, 0.68 mmol) in dry dichloromethane (3 ml), and dimethyl sulfoxide (186
- the same procedure as in Example 44 was carried out using 1,2.61 mol) and triethylamine (435 ⁇ 1, 3.10 minol) to obtain the title compound (llmg, 323 ⁇ 40) as a pale yellow solid.
- HN R5 0.05 (s, 6H), 0.06 (s, 3H), 0.ll (s, 3H), 0.85 (s, 3H), 0.86 (s, 9H), 0.8
- UVA max nm 242, 258, 270, 281, 293.
- Example 48 The compound obtained in Example 48 (931 mg, 1.3 mmol) was dissolved in dichloromethane (40 ml), selenium dioxide (5.1 mg, 45.5 / mol), and t-butyl hydride peroxide (70 °, 422 mg, 4.68 mraol) was added and stirred at room temperature for 27 hours.
- the reaction solution was diluted with dichloromethane, washed with saturated saline, dried over anhydrous magnesium sulfate, and the solvent was distilled off.
- UV max nm 210, 258.
- Example 51 1-35-bis (t-butyldimethylsilyloxy) -1 20 (S)-(3-hydroxy-3-methylbutylthio) -1 16-year-old xopregna 1,7-gen and 1 Na, 3 / S-bis (t-butyldimethylsilyloxy)
- UV A .ax nm 270, 281, 293.
- UVA max mn 270, 281, 293.
- Example 52 la 33-Bis (t-butyldimethylsilyloxy) -1 20 (S) -1 (3-hydroxy-13-methylbutylthio) -1 16-year-old xopregna-5,7-gen and la, 3 —bis (t-butyldimethylsilyloxy) -20
- UVA raa x nm 270, 281, 293.
- UV max nm 270, 281, 293.
- Example 54 3-bis (t-butyldimethylsilyloxy)-1 2 O (S)-1-(4-hydroxy-4-methylpentylthio)-1-16-year-old xopregna-5,7-gen and 1 Na, 3 ⁇ -bis (t-butyldimethylsilyloxy) 1 2
- UVA raa x nm 270, 281, 293.
- UVA.ax nm 270, 281, 293.
- Example 55 1 ⁇ , 3yS-Bis (t-butyldimethylsilyloxy) -1 20 (S)-(3-ethyl-1-3-hydroxypentylthio) -16-oxopredana —5,7-Gen And 1, 33-bis (t-butyldimethylsilylloquine) 1 20 (R) 1 (3-ethyl 3-hydroxypentylthio) 1,16-oxopregna 1,7-gen
- Example 44 The compound obtained in Example 44 (152 mg, 273 / mol), 0.1 M sodium tetraborate (4.2 ml), 3-ethyl-13-hydroxy-11-pentanethiol (140 ⁇ 1), tetrahydrofuran (4.2
- UV m ax nm 270, 281 , 293.
- Example 56 1 ⁇ , 3 ⁇ -bis (t-butyldimethylsilyloxy) -120 (S)-(3-hydroquin-1-methylbutyl-thio) -1 16; 3-hydroquin-pregna-5,7- 1,3-S-bis (t-butyldimethylsilyloxy) -20 (S)-(3-hydroxy-13-methylbutylthio) 1-116-hydroxypregna-1,7-gen
- the 20S form (113 mg, 167 / mol) of the compound obtained in Example 51 was dissolved in tetrahydrofuran (3.5 ml), lithium aluminum hydride (10.lmg, 266 zmol) was added little by little, and the mixture was added at room temperature. After stirring for 30 minutes, the mixture was quenched with a 10% aqueous solution of sodium hydroxide, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous magnesium sulfate.
- UV .a x nm 271, 282, 294.
- UVA max nm 270, 281, 293.
- Example 57 1-, 3-bis (t-butyldimethylsilyloxy) -20 (R)-(3-hydroxy-3-methylbutylthio) -1 16-hydroxypregner 5,7-gen and 1 ⁇ , 33-Bis (t-butyldimethylsilyloxy) -1 20 (R) -1 (3-Hydroxyquin-3-methylbutylthio) 1-116 Hydroxycypregner 5,7-Gen
- UV ro ax nm 270, 282, 293.
- UVA max nm 270, 282, 293.
- Example 58 1,3 / 3-Bis (t-butyldimethylsilyloxy) -20 (S)-(4-ethyl-4-hydroquinequinolthio) -1 16; 3-hydroxyregna-5, 7-Gen and 1,3 / 3-bis (t-butyldimethylsilyloxy) — 20 (S) — (4-Ethyl 4-Hydroxyquinhexylthio) -1 16 ⁇ -Hydroxypregna 1,7—Gen
- UVA max nm 270, 282, 294.
- UVA.ax nm 270, 281, 293.
- UVA m ax nm 270, 282 , 293.
- Example 60 1,3-bis (t-butyldimethylsilyloxy) -1 20 (S)-(4-hydroxy-4-methylpentylthio) -1 16; 5-hydroxypregna-1,7-gen And 1,3-bis (t-butyldimethylsilyloxy) -20 (S)-(4-hydroxy-14-methylpentylthio) -16 ⁇ -hydroxypregna-1,7-gen
- UV A max nm 270, 282, 293.
- J HM 6 0.05 (s, 3H), 0.06 (s, 6H), 0.10 (s, 3H), 0.72 (s, 3H), 0.88 (s, 21H), 1.
- UVA max nm 270, 282, 293.
- Example 56 Using the 2 OR form (91. Img, 132 mol), tetrahydrofuran (2.5 ml), and lithium aluminum hydride (8.0 mg, 211 mol) of the compound obtained in Example 54, Example 56 The reaction was carried out in the same manner as in the synthesis of, followed by purification by preparative thin-layer chromatography (2 plates, dichloromethane: ethanol-20: 1, developed 5 times) to give the title compound (57.0 mg, 62! ⁇ ⁇ ) as a colorless oil. ).
- UV .ax nm 270, 281, 293.
- Example 62 1,3-Bis (t-butyldimethylsilyloxy) -1 20 (S) 1- (3-ethyl-3-hydroxyquinpentylthio) -1 16; ⁇ -hydroxypregna-5,7- Gen and la, 3; S-bis (t-butyldimethylsilyloxy) -20 (S) ⁇ (3-Ethyru 3-Hydroxypentylthio) 1 16 ⁇ -Hydroxypregna 5, 7—Gen
- UVA m ax nm 271, 282 , 294.
- UVA max nm 270, 281, 293.
- UVA max nm 270, 281, 293.
- Example 65 20 (S)-(3-hydroxy-3-methylbutylthio) 1-1,3 / 3,16 trihydroxypregna-1,7-gen
- UVA raax nm 270, 282, 293.
- UVA max nm 270, 281, 293.
- UVA raa x nm 270, 281, 293.
- UVA raax nm 271, 282, 293.
- Example 70 (R) — (4-Ethyl-4-hydroquinhexylthio) -1-a, 3 ⁇ , 16—trihydroxypregna-1,7-gen
- UVA max nm 271, 282, 293.
- UVA maJt nm 270, 282, 293.
- UVA ro ax nm 271, 282, 294.
- UVA raa x nm 271, 282, 293.
- UV A max nm 270, 281, 293.
- Example 77 After the reaction was carried out in the same manner as in Example 77 using the compound obtained in Example 65 (11.5 mg, 25.5 mol) (light irradiation: 2.5 minutes), preparative thin-layer chromatography (one sheet, dichloromethane: The residue was purified by ethanol (6: 1, developed 5 times) to give the title compound (0.7 mg, 6%) as a colorless oil.
- Example 77 After the reaction was carried out in the same manner as in Example 77 using the compound (21.3 mg, 43.2 ⁇ mol) obtained in Example 68 (light irradiation: 2.5 minutes), preparative thin-layer chromatography (one plate, dichloromethane: The residue was purified by ethanol (10: 1, developed three times) to give the title compound (3.9 mg, 18%) as a colorless oil.
- IB (neat): 3400, 2930, 1450, 1380, 1050cm- 1 .
- UVAmax nm 262, A mi n nm: 227.
- UVAmax nm 262
- a rain nm 227.
- KGM / DMEM (1: 1) 3 days 37 ° C, 5% C0 2 in a medium, cultured 3 ⁇ 4 in 953 ⁇ 4air: T ivy.
- ⁇ indicates that there is a significant difference at a risk rate of 5%, ⁇ is 1%, and ⁇ is 0.1%.
- the compounds of the present invention have strong human keratinocyte growth inhibitory activity.
- the compound of the present invention a vitamin D derivative in which the 22-position is substituted with a sulfur atom, has a strong keratinocyte growth inhibitory action.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95914550A EP0755922B1 (en) | 1994-04-11 | 1995-04-10 | 22-thiavitamin d3 derivative |
US08/718,499 US5824811A (en) | 1994-04-11 | 1995-04-10 | 22-Thiavitamin D3 derivatives |
RU96121801A RU2142941C1 (ru) | 1994-04-11 | 1995-04-10 | Производные 22-тиавитамина d3, способ их получения, способы получения соединений, соединения |
KR1019960705708A KR100244060B1 (ko) | 1994-04-11 | 1995-04-10 | 22-티아비타민 디3 유도체 |
AT95914550T ATE195513T1 (de) | 1994-04-11 | 1995-04-10 | 22-thiavitamin-d3-derivate |
BR9507355A BR9507355A (pt) | 1994-04-11 | 1995-04-10 | Derivodos de 22-tiavitamina D3 |
AU21482/95A AU2148295A (en) | 1994-04-11 | 1995-04-10 | 22-thiavitamin d3 derivative |
DE69518410T DE69518410T2 (de) | 1994-04-11 | 1995-04-10 | 22-thiavitamin-d3-derivate |
MX9604735A MX9604735A (es) | 1995-04-10 | 1995-04-10 | Derivados de la 22-tiavitamina d3. |
DK95914550T DK0755922T3 (da) | 1994-04-11 | 1995-04-10 | 22-Thiavitamin D3-derivat |
GR20000402009T GR3034322T3 (en) | 1994-04-11 | 2000-09-01 | 22-thiavitamin d 3 derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/107366 | 1994-04-11 | ||
JP10736694 | 1994-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995027697A1 true WO1995027697A1 (fr) | 1995-10-19 |
Family
ID=14457272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/000699 WO1995027697A1 (fr) | 1994-04-11 | 1995-04-10 | Derive de la 22-thiavitamine d¿3? |
Country Status (14)
Country | Link |
---|---|
US (1) | US5824811A (ja) |
EP (1) | EP0755922B1 (ja) |
KR (1) | KR100244060B1 (ja) |
CN (1) | CN1046502C (ja) |
AT (1) | ATE195513T1 (ja) |
AU (1) | AU2148295A (ja) |
BR (1) | BR9507355A (ja) |
DE (1) | DE69518410T2 (ja) |
DK (1) | DK0755922T3 (ja) |
ES (1) | ES2150560T3 (ja) |
GR (1) | GR3034322T3 (ja) |
PT (1) | PT755922E (ja) |
RU (1) | RU2142941C1 (ja) |
WO (1) | WO1995027697A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554599A (en) * | 1992-12-23 | 1996-09-10 | Leo Pharmaceutical Products Ltd. | 22-thio vitamin D derivatives |
EP0870503A1 (en) * | 1995-12-28 | 1998-10-14 | Chugai Seiyaku Kabushiki Kaisha | Malignant tumor metastasis inhibitors |
US6869940B2 (en) | 1995-12-28 | 2005-03-22 | Chugai Seiyaku Kabushiki Kaisha | Malignant tumor metastasis inhibitors |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050123185A (ko) | 1996-12-20 | 2005-12-29 | 쥬가이 세이야쿠 가부시키가이샤 | 16-엔-비타민 d 유도체 |
US6184398B1 (en) * | 1996-12-20 | 2001-02-06 | Chugai Seiyaku Kabushiki Kaisha | 16-ene-vitamin D derivatives |
CA2289209C (en) * | 1997-05-16 | 2006-07-25 | Women & Infants Hospital | Cyclic ether vitamin d3 compounds, 1.alpha. (oh) 3-epi-vitamin d3 compounds and uses thereof |
DE60044090D1 (de) * | 1999-08-27 | 2010-05-12 | Hiroaki Takayama | Vitamin-d-derivate mit substituenten an der 2-alpha-position |
GB2364231A (en) * | 2000-04-05 | 2002-01-23 | Bush Boake Allen Ltd | Flavouring agent |
US6899911B2 (en) * | 2000-04-05 | 2005-05-31 | International Flavors & Fragrances, Inc. | Ethyl 4-(thioacetoxy)butyrate as a flavoring agent and methods for preparing and using same |
AU2001248777A1 (en) * | 2000-04-19 | 2001-10-30 | Chugai Seiyaku Kabushiki Kaisha | Vitamin d derivatives |
CN102617690B (zh) | 2000-06-15 | 2015-07-08 | 中外制药株式会社 | 维生素d衍生物 |
CA2750659C (en) | 2009-01-27 | 2017-11-21 | Berg Biosystems, Llc | Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy |
EP3603646B1 (en) | 2009-08-14 | 2024-04-03 | BPGbio, Inc. | Vitamin d3 and analogs thereof for treating alopecia |
SG11201509715UA (en) | 2013-05-29 | 2015-12-30 | Berg Llc | Preventing or mitigating chemotherapy induced alopecia using vitamin d |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61267550A (ja) | 1984-12-28 | 1986-11-27 | Chugai Pharmaceut Co Ltd | 9,10−セコ−5,7,10(19)−プレグナトリエン誘導体 |
JPH03188061A (ja) * | 1989-12-15 | 1991-08-16 | Chugai Pharmaceut Co Ltd | 新規な22―オキサビタミンd誘導体 |
JPH0489473A (ja) * | 1990-07-26 | 1992-03-23 | Kuraray Co Ltd | 1α―ヒドロキシタキステロール誘導体の製造方法 |
JPH05505613A (ja) | 1990-03-30 | 1993-08-19 | レオ・ファーマシューティカル・プロダクツ・リミテッド・エイ/エス(レーベンス・ケミスケ・ファブリック・プロデュクチオンスアクチーセルスカブ) | 新規ビタミンd類似体 |
WO1994014766A1 (en) * | 1992-12-23 | 1994-07-07 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) | Novel vitamin d analogues |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3577552D1 (de) * | 1984-11-27 | 1990-06-13 | Chugai Pharmaceutical Co Ltd | Vitamin d-derivate und verfahren zu deren herstellung. |
DE4220757A1 (de) * | 1992-06-24 | 1994-01-05 | Schering Ag | Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
JP4089473B2 (ja) * | 2003-03-12 | 2008-05-28 | 株式会社ジェイテクト | ブラケット一体型リザーブタンク |
-
1995
- 1995-04-10 PT PT95914550T patent/PT755922E/pt unknown
- 1995-04-10 BR BR9507355A patent/BR9507355A/pt not_active IP Right Cessation
- 1995-04-10 AT AT95914550T patent/ATE195513T1/de not_active IP Right Cessation
- 1995-04-10 DE DE69518410T patent/DE69518410T2/de not_active Expired - Lifetime
- 1995-04-10 WO PCT/JP1995/000699 patent/WO1995027697A1/ja active IP Right Grant
- 1995-04-10 EP EP95914550A patent/EP0755922B1/en not_active Expired - Lifetime
- 1995-04-10 DK DK95914550T patent/DK0755922T3/da active
- 1995-04-10 RU RU96121801A patent/RU2142941C1/ru not_active IP Right Cessation
- 1995-04-10 AU AU21482/95A patent/AU2148295A/en not_active Abandoned
- 1995-04-10 KR KR1019960705708A patent/KR100244060B1/ko not_active IP Right Cessation
- 1995-04-10 CN CN95193058A patent/CN1046502C/zh not_active Expired - Fee Related
- 1995-04-10 US US08/718,499 patent/US5824811A/en not_active Expired - Lifetime
- 1995-04-10 ES ES95914550T patent/ES2150560T3/es not_active Expired - Lifetime
-
2000
- 2000-09-01 GR GR20000402009T patent/GR3034322T3/el not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61267550A (ja) | 1984-12-28 | 1986-11-27 | Chugai Pharmaceut Co Ltd | 9,10−セコ−5,7,10(19)−プレグナトリエン誘導体 |
JPH03188061A (ja) * | 1989-12-15 | 1991-08-16 | Chugai Pharmaceut Co Ltd | 新規な22―オキサビタミンd誘導体 |
JPH05505613A (ja) | 1990-03-30 | 1993-08-19 | レオ・ファーマシューティカル・プロダクツ・リミテッド・エイ/エス(レーベンス・ケミスケ・ファブリック・プロデュクチオンスアクチーセルスカブ) | 新規ビタミンd類似体 |
JPH0489473A (ja) * | 1990-07-26 | 1992-03-23 | Kuraray Co Ltd | 1α―ヒドロキシタキステロール誘導体の製造方法 |
WO1994014766A1 (en) * | 1992-12-23 | 1994-07-07 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) | Novel vitamin d analogues |
Non-Patent Citations (3)
Title |
---|
MURAYAMA ET AL., BIOORG. MED. CHEM. LETT., vol. 2, 1992, pages 1289 |
MURAYAMA ET AL., CHEM. PHARM. BULL., vol. 34, 1986, pages 4410 |
See also references of EP0755922A4 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554599A (en) * | 1992-12-23 | 1996-09-10 | Leo Pharmaceutical Products Ltd. | 22-thio vitamin D derivatives |
EP0870503A1 (en) * | 1995-12-28 | 1998-10-14 | Chugai Seiyaku Kabushiki Kaisha | Malignant tumor metastasis inhibitors |
EP0870503A4 (en) * | 1995-12-28 | 2000-11-02 | Chugai Pharmaceutical Co Ltd | INHIBITORS OF MALIGNANT TUMOR METASTASES |
US6566351B1 (en) | 1995-12-28 | 2003-05-20 | Chugai Seiyaku Kabushiki Kaisha | Malignant tumor metastasis inhibitors |
US6869940B2 (en) | 1995-12-28 | 2005-03-22 | Chugai Seiyaku Kabushiki Kaisha | Malignant tumor metastasis inhibitors |
Also Published As
Publication number | Publication date |
---|---|
ATE195513T1 (de) | 2000-09-15 |
KR100244060B1 (ko) | 2000-02-01 |
DK0755922T3 (da) | 2000-11-13 |
KR970702245A (ko) | 1997-05-13 |
PT755922E (pt) | 2000-11-30 |
RU2142941C1 (ru) | 1999-12-20 |
CN1046502C (zh) | 1999-11-17 |
EP0755922A1 (en) | 1997-01-29 |
EP0755922A4 (en) | 1997-07-02 |
US5824811A (en) | 1998-10-20 |
ES2150560T3 (es) | 2000-12-01 |
DE69518410D1 (de) | 2000-09-21 |
AU2148295A (en) | 1995-10-30 |
DE69518410T2 (de) | 2000-12-14 |
EP0755922B1 (en) | 2000-08-16 |
BR9507355A (pt) | 1997-09-09 |
GR3034322T3 (en) | 2000-12-29 |
CN1148380A (zh) | 1997-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995027697A1 (fr) | Derive de la 22-thiavitamine d¿3? | |
FI109996B (fi) | Menetelmä terapeuttisesti käyttökelpoisen D-vitamiinisarjan 25-karboksyylihappojohdannaisten valmistamiseksi | |
JP3706104B2 (ja) | ビタミンd誘導体 | |
EP0947504B1 (en) | 16-ene-vitamin d derivatives | |
WO2007142158A1 (ja) | 9,10-セコプレグナン誘導体及び医薬 | |
US20030195176A1 (en) | Vitamin d derivatives | |
AU755701B2 (en) | Method for making hydroxy-25-ene-vitamin D compounds | |
US6184398B1 (en) | 16-ene-vitamin D derivatives | |
JP4012293B2 (ja) | 16−エン−ビタミンd誘導体 | |
JP3759639B2 (ja) | 22−チアビタミン▲d3▼誘導体 | |
JPH0374656B2 (ja) | ||
Kubodera et al. | 22-Thiavitamin D 3 derivatives | |
EP1219599B1 (en) | Vitamin d derivatives having substituents at the 2 alpha-position | |
WO2021033766A1 (ja) | ビタミンd活性を有するリトコール酸誘導体 | |
JP3908799B2 (ja) | 神経線維腫治療剤 | |
JP3882027B2 (ja) | 20−エピ−22−エチル−23,24−デヒドロ−24,24−ジホモビタミンd誘導体及びその合成中間体 | |
AU2005234636B2 (en) | Vitamin D derivatives | |
JPH08113559A (ja) | 24−オキソ−22−オキサビタミン▲d3▼誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95193058.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS KE KG KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: MX |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08718499 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995914550 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019960705708 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1995914550 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995914550 Country of ref document: EP |